Cargando…

Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients

Immunosuppressive drugs commonly used in the treatment of psoriatic arthritis make patients more susceptible to viral, bacterial, and fungal infections because of their mechanism of action. They not only increase the risk of new infections but also act altering the natural course of preexisting infe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laurenti, R., Giovannangeli, F., Gubinelli, E., Viviano, M. T., Errico, A., Leoni, L., Ballanti, E., Migliore, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623386/ https://www.ncbi.nlm.nih.gov/pubmed/23606869 http://dx.doi.org/10.1155/2013/410521

Ejemplares similares

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis
por: Martin-Martin, LS, et al.
Publicado: (2017)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Brain abscess in a patient with psoriatic arthritis treated with adalimumab: A case report
por: Lo, Yu-Pei, et al.
Publicado: (2020)

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Krawczyk, Agata, et al.
Publicado: (2021)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
por: Van den Bosch, F, et al.
Publicado: (2010)

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
por: Teoli, M., et al.
Publicado: (2012)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Treating psoriatic arthritis: how effective are TNF antagonists?
por: Gottlieb, Alice B, et al.
Publicado: (2004)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis
por: Pirowska, Magdalena M., et al.
Publicado: (2015)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, Robert, et al.
Publicado: (2019)

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Tektonidou, Maria G., et al.
Publicado: (2020)

Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
por: Palmer, Jacqueline B., et al.
Publicado: (2016)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
por: Behrens, Frank, et al.
Publicado: (2018)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection
por: Atteno, Mariangela, et al.
Publicado: (2014)

S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Influenza H1N1 infection in a patient with psoriatic arthritis in treatment with Adalimumab: a case report
por: Serrato, Varlei A., et al.
Publicado: (2010)

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2022)

TNF polymorphisms are associated with the development of joint erosions in psoriatic arthritis
por: Kane, D, et al.
Publicado: (2003)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy
por: Anghel, Daniela, et al.
Publicado: (2023)

Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review
por: Shimojima, Yasuhiro, et al.
Publicado: (2012)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
por: Makos, Anaïs, et al.
Publicado: (2022)

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?
por: Curry, Philippa D. K., et al.
Publicado: (2022)

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
por: Cordtz, Rene Lindholm, et al.
Publicado: (2022)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis
por: Jin, Yinzhu, et al.
Publicado: (2021)

Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007)

Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3kibq9kvkih76mbi4dkc2es6ej